Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,264 across all filing types
Latest filing 2018-03-15 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于召开2017年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2017 Annual General Meeting (AGM) of 葵花药业集团股份有限公司, including the meeting date, agenda items, voting procedures, and proxy forms. It contains no financial statements or results but focuses on informing shareholders about the AGM logistics and agenda. The document length is over 6000 characters, indicating it is not a brief announcement but a full AGM notice. This matches the definition of 'AGM Information' (AGM-R), which includes presentations and materials shared during the AGM. It is not an Annual Report (10-K) or any other financial report, nor is it a voting result announcement (DVA) or proxy solicitation (PSI). Therefore, the correct classification is AGM Information (AGM-R).
2018-03-15 Chinese
2017年度董事会工作报告
Management Reports Classification · 95% confidence The document is titled as 葵花药业集团股份有限公司 2017 年度董事会工作报告, which translates to '2017 Annual Board of Directors Work Report'. It contains detailed financial data for the year 2017, including total assets, net profit, revenue, costs, R&D investment, cash flow analysis, and business development review. The document is comprehensive, covering the company's operational and financial performance over the full fiscal year 2017. It is not a short announcement or a certification but a full report with substantive financial data and management discussion. The content aligns with a Management Report or Management Discussion and Analysis (MDA) rather than a full Annual Report (10-K) or an Audit Report (AR). The focus is on the board's work and management's review of the year's performance, which fits the Management Reports (MDA) category.
2018-03-15 Chinese
东海证券股份有限公司关于公司2017年度募集资金存放及使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from Donghai Securities regarding the 2017 annual fundraising funds deposit and usage of Kuihua Pharmaceutical Group Co., Ltd. It references regulatory rules related to securities issuance and listing, and includes detailed financial data on fundraising amounts, usage, bank accounts, investment projects, and compliance with regulations. The document is a formal audit or verification report on the use of raised funds, issued by the sponsor institution, including references to audit reports and bank statements. It does not represent a full annual report or interim financial report, nor is it a simple announcement or certification. The content aligns with an Audit Report / Information filing, as it focuses on the audit and verification of fundraising fund usage and compliance, rather than full financial statements or earnings results. FY 2017
2018-03-15 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or compliance checklist rather than a full financial report or audit report. It does not contain financial statements, earnings data, or management discussion and analysis. It is also not an announcement or a brief summary but a detailed internal control compliance document. This type of document fits best under Regulatory Filings (RNS) as it is a regulatory compliance disclosure that does not fit into other specific categories like Annual Report, Audit Report, or Management Reports.
2018-03-15 Chinese
关于举行2017年度业绩网上说明会的通知
Investor Presentation Classification · 90% confidence The document is a notice about holding an online performance briefing for the 2017 annual results, scheduled for a specific date and time. It invites investors to participate in a webcast with company executives. The document does not contain actual financial data or detailed financial statements but is an announcement of an event related to the annual results. It is not the annual report itself, nor a transcript or detailed presentation. Given the nature of the document as a notice for an annual results briefing, it fits best under 'Investor Presentation' (IP) as it is a detailed presentation event for investors focusing on financials and company performance.
2018-03-15 Chinese
关于变更注册资本及修改公司章程的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding changes in the company's registered capital and amendments to the company bylaws (章程). It details a capital increase through a stock dividend and the corresponding amendment to the registered capital and share count. The document references board meeting resolutions and states that these changes require shareholder approval at the annual general meeting. The document is short (1065 characters) and primarily serves as a formal announcement of corporate governance and capital structure changes, not a full financial report or detailed analysis. It does not contain financial statements or detailed financial data. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements about new share issues or capital changes.
2018-03-15 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.